Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Deng, Linaa; 1 | Zheng, Wenxinb; 1 | Dong, Xueshuangb | Liu, Jianghuab | Zhu, Chunyub | Lu, Danb | Zhang, Jinb | Song, Laijunb | Wang, Yuchaob | Deng, Danb; *
Affiliations: [a] Department of Surgery, Daqing Longnan Hospital, Daqing, Heilongjiang, China | [b] Department of Neurology, Daqing Oilfield General Hospital, Daqing, Heilongjiang, China
Correspondence: [*] Corresponding author: Dan Deng, Department of Neurology, Daqing Oilfield General Hospital, 9 Zhongkang Street, Daqing 163001, Heilongjiang, China. Tel.: +86 4595805735; Fax: +86 4595805736; E-mail: dandengdq@163.com.
Note: [1] Lina Deng and Wenxin Zheng contributed equally to this study and should be considered as co-first author.
Abstract: BACKGROUND: Glioblastoma (GBM) is the most common and most fatal primary brain cancer in adults. Due to the complex nature of GBM, its pathogenesis still remain unclear. Accumulating evidence suggest that chemokine receptor CXCR7 contribute to the development of various types of tumors. OBJECTIVE: We aim to examine the prognostic significance of CXCR7 in GBM. METHODS: CXCR7 were first detected by Immunohistochemistry. The association between CXCR7 and overall survival (OS) were examined. Moreover, multivariate analyses were conducted to evaluate the prognostic factors in GBM. RESULTS: Of all 146 GBM patients recruited, 77 were in the high-expression subgroup, the rest 69 were in low-expression subgroup. There are no differences between these two subgroups in terms of age, gender, family history of cancer, extent of surgery, chemotherapy, radiotherapy, KPS, MGMT methylation status and tumor size. However, high CXCR7 expression was robustly correlated with poor OS in GBM. Multivariate analysis confirmed age, KPS scores, chemotherapy, IDH1 mutation, MGMT methylation and CXCR7 were independent factors in survival prognosis. CONCLUSIONS: CXCR7 may involve in the clinical GBM progression, and CXCR7 could be a valuable prognostic marker in the treatment of GBM.
Keywords: Glioblastoma, CXCR7, prognostic biomarker, survival
DOI: 10.3233/CBM-151430
Journal: Cancer Biomarkers, vol. 20, no. 1, pp. 1-6, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl